Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
WEDNESDAY, Nov. 20, 2024 -- A number of adults with outpatient medically attended respiratory syncytial virus (MA-RSV) infection experience hospitalization within 28 days, with a higher proportion among high-risk subgroups, according to a study published online Nov. 19 in JAMA Network Open.
Suzanne N. Landi, Ph.D., M.P.H., from Pfizer Inc. in New York City, and colleagues examined the absolute risk for 28-day all-cause hospitalization following outpatient MA-RSV infection in adults in a cohort study using data from three databases (the Optum deidentified Integrated Claims-Clinical dataset, TriNetX Linked, and Veradigm Network Electronic Health Record [VNEHR] database linked with claims). Data were analyzed across six RSV years from Oct. 1, 2016, to Sept. 30, 2022. The main outcome was all-cause 28-day hospitalization among all adults and a high-risk subgroup (with asthma, chronic obstructive pulmonary disease [COPD], congestive heart failure [CHF], or age 65 years and older).
The analyses included 67,239 MA-RSV infections (2,771 from Optum, 7,442 from TriNetX, and 57,026 from VNEHR). The prevalence of comorbidity was 20.0 to 30.5 percent for COPD, 14.6 to 24.4 percent for CHF, and 30.0 to 34.4 percent for asthma. Individuals aged 65 years and older accounted for 14.0 to 54.5 percent of the participants. The researchers found that 6.2, 6.0, and 4.5 percent were hospitalized in Optum, TriNetX, and VNEHR, respectively. In the high-risk subgroup, the corresponding proportions were 7.6, 8.5, and 6.5 percent, respectively.
"These results highlight the unmet medical need for outpatient interventions and preventive measures that can reduce hospitalizations," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Pfizer, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
MONDAY, Aug. 25, 2025 -- Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024...
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
WEDNESDAY, July 30, 2025 -- Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according...
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 -- In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.